Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3 -ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation

(2016) Gary J. Schiller et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group

(2015) Thomas Schroeder et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

(2015) C. Schmid et al.   BLOOD

5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft

(2015) J Steinmann et al.   BONE MARROW TRANSPLANTATION

High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation

(2015) Tiago De Freitas et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells

(2015) E Chang et al.   LEUKEMIA

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

(2014) B Tessoulin et al.   BONE MARROW TRANSPLANTATION

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

(2013) Marcos de Lima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia

(2013) S. D. Baker et al.   CLINICAL CANCER RESEARCH

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib

(2011) Manish Sharma et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

(2011) C. Schmid et al.   BLOOD

Molecular remission of FLT3-ITD+ positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib

(2011) W H Krüger et al.   BONE MARROW TRANSPLANTATION

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

(2010) Thomas Schroeder et al.   ACTA HAEMATOLOGICA

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

(2010) David L. Porter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation

(2010) Javier Bolaños-Meade et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning

(2010) T Lange et al.   LEUKEMIA

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report

(2010) J. Winkler et al.   LEUKEMIA RESEARCH

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

(2009) A Czibere et al.   BONE MARROW TRANSPLANTATION

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

(2009) Elias Jabbour et al.   CANCER

Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

(2008) N.N. Safaian et al.   LEUKEMIA RESEARCH